J. Rech

发表

Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients

G. Schett, K. Tascilar, A. Kleyer, 2022, Annals of the Rheumatic Diseases.

Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis

Md. Mohaiminul Islam, P. Hu, G. Schett, 2021, Frontiers in Immunology.

Refractory SLE patients respond to the proteasome inhibitor bortezomib

G. Schett, F. Hiepe, G. Burmester, 2012 .

Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial

Hanns-Martin Lorenz, G. Schett, M. Englbrecht, 2021, The Lancet Rheumatology.

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

J. Stone, M. Aringer, D. Blockmans, 2021, Rheumatology.

IgA anti-citrullinated protein antibodies (IgA ACPA) are associated with flares during DMARD tapering in rheumatoid arthritis.

G. Schett, H. Bang, M. Sokolova, 2021, Rheumatology.

Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’

G. Schett, K. Tascilar, A. Kleyer, 2021, Annals of the Rheumatic Diseases.

Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors

A. Hoerning, F. Losch, J. Rech, 2023, Journal of clinical medicine.

POS0531 ABATACEPT DELAYS THE DEVELOPMENT OF RA– CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS

E. Naredo, J. Strunk, G. Schett, 2022, Annals of the Rheumatic Diseases.